Stock Events

Stock Events

Avadel Pharmaceuticals 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Jazz Pharmaceuticals
JAZZ
Mkt Cap15.32B
Jazz Pharmaceuticals focuses on developing and commercializing products for sleep disorders, directly competing with Avadel's narcolepsy treatments.
Axsome Therapeutics
AXSM
Mkt Cap12.03B
Axsome Therapeutics is involved in developing therapies for central nervous system disorders including narcolepsy, making it a direct competitor.
Heron Therapeutics
HRTX
Mkt Cap78.44M
Heron Therapeutics develops treatments for postoperative pain and other conditions, competing in the broader pharmaceutical market against Avadel's offerings.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap38.37B
Teva Pharmaceutical Industries has a broad portfolio that includes treatments for sleep disorders, directly competing with Avadel's narcolepsy drug.
Biogen
BIIB
Mkt Cap29.4B
Biogen focuses on neurological diseases including sleep disorders, positioning it as a competitor in the same therapeutic area as Avadel.
Johnson & Johnson
JNJ
Mkt Cap618.61B
Johnson & Johnson, through its pharmaceutical division Janssen, competes across a wide range of therapeutic areas, including sleep disorders.
Novartis
NVS
Mkt Cap293.94B
Novartis offers a broad range of healthcare products that compete in various therapeutic areas, including those targeted by Avadel.
Pfizer
PFE
Mkt Cap137.76B
Pfizer has a diverse portfolio of drugs, including those for neurological conditions, competing with Avadel's focus areas.
Merck
MRK
Mkt Cap305.12B
Merck & Co. competes in the pharmaceutical market with a broad product line, including treatments for conditions that overlap with Avadel's target markets.

About

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Show more...
CEO
Mr. Gregory J. Divis Jr.
Employees
188
Country
France
ISIN
US05337M1045

Listings

MU
DE
AWK1.MU
STU
DE
AWK1.STU
BOATS
BOATS
AVDL.BOATS

0 Comments

Share your thoughts

FAQ

What is Avadel Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Avadel Pharmaceuticals stocks are traded under the ticker AWK1.MU.
How many employees does Avadel Pharmaceuticals have?▼
As of July 25, 2026, the company has 188 employees.
In which sector is Avadel Pharmaceuticals located?▼
Avadel Pharmaceuticals operates in the Health & Wellness sector.
When did Avadel Pharmaceuticals complete a stock split?▼
Avadel Pharmaceuticals has not had any recent stock splits.
Where is Avadel Pharmaceuticals headquartered?▼
Avadel Pharmaceuticals is headquartered in Dublin, France.